Home » Shire Phase II Study of MDD Adjunctive Therapy Vyvanse Capsules Meets Endpoints
Shire Phase II Study of MDD Adjunctive Therapy Vyvanse Capsules Meets Endpoints
Shire reported results from a Phase II trial of its adjunctive therapy Vyvanse capsules for patients suffering from major depressive disorder with the change in global executive composite T-score of the behavioral rating inventory of executive function - adult version assessment being the primary efficacy measure.
RTT News
RTT News
Upcoming Events
-
07May
-
14May
-
30May